Replacement Amendment and Response Under 37 C.F.R. §1.116

Page 12 of 14

Serial No.: 10/051,719 Confirmation No.: 8633 Filed: 16 January 2002

For: ANTISPECTIF COMPOSITIONS AND METHODS

Remarks

The Final Office Action mailed 26 August 2005 has been received and reviewed. Claims 2-7, 9, 10, 14, 15, 17, 19-22, 25-29, 37, 39-43, 54, and 58 having been amended, claims 1, 13, 38, 44-53, and 57 having been canceled, the pending claims are 2-12, 14-37, 39-43, 54-56, and 58-63. Applicants respectfully request that the present Amendment and Response Under 37 C.F.R. §1.116 replace the previously filed Amendment and Response Under 37 C.F.R. §1.116 dated 4 November 2005. Reconsideration and withdrawal of the rejections are respectfully requested.

Interview Summary Record

Applicants thank Examiners Choi and Padmanabhan for the courtesy extended in the telephone interview dated 26 October 2005 with Ann Mueting (Applicants' Representative) and Matt Scholz and Dan McIntyre.

During the interview potentially allowable subject was discussed. It was agreed that amendments presented herein would be submitted by Applicants and considered and entered by the Examiner.

Obviousness-Type Double Patenting Rejection

Claims 1-21, 25-30, 37-39, 41-43, and 54-63 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7, 16-25, 27, 29-44, and 47-60 of copending Application No. 10/922,262 or claims 1-7, 16-25, 27, 29-44, and 47-59 of U.S. Patent No. 6,838,078 in view of Kross et al. (U.S. Patent No. 5,618,841), brink et al. (U.S. Patent No. 5,173,291) and Beach (U.S. Patent No. 3,380,923) in further view of Talwalker et al. (U.S. Patent No. 5,462,714) and Richter et al. (U.S. Patent No. 6,379,685) in further view of Samour et al. (U.S. Patent No. 5,807,957). Upon an indication of otherwise allowable subject matter and in the event this rejection is maintained, Applicants will provide an appropriate response.

Replacement Amendment and Response Under 37 C.F.R. §1.116

Page 13 of 14

Serial No.: 10/051,719 Confirmation No.: 8633 Filed: 16 January 2002

For: ANTISPECTIF COMPOSITIONS AND METHODS

The 35 U.S.C. §103 Rejection

The Examiner rejected claims 1-21, 25-30, 37-39, 41-43, and 54-63 under 35 U.S.C. §103(a) as being unpatentable over Kross et al. (U.S. Patent No. 5,618,841) in view of Brink et al. (U.S. Patent No. 5,173,291) and Beach (U.S. Patent No. 3,380,923), in further view of Talwalker et al. (U.S. Patent No. 5,462,714) and Richter et al (U.S. Patent No. 6,379,685) in further view of Samour et al. (U.S. Patent No. 5,807,957). This rejection is respectfully traversed and rendered moot in view of the amended claims. Applicants reserve the right to present arguments in a continuing application for patentability of the previously pending claims.

Replacement Amendment and Response Under 37 C.F.R. §1.116

Serial No.: 10/051.719 Confirmation No.: 8633 Filed: 16 January 2002

For: ANTISPECTIF COMPOSITIONS AND METHODS

Page 14 of 14

<u>Summary</u>

It is respectfully submitted that the pending claims 2-12, 14-37, 39-43, 54-56, and 58-63 are in condition for allowance and notification to that effect is respectfully requested. The Examiner is invited to contact Applicants' Representatives, at the belowlisted telephone number, if it is believed that prosecution of this application may be assisted thereby.

> Respectfully submitted Βv Mueting, Raasch & Gebhardt, P.A. P.O. Box 581415 Minneapolis, MN 55458-1415 Phone: (612) 305-1220 Facsimile: (612) 305-1228

premiser

Ann M. Mueting

Reg. No. 33,977

Direct Dial (612) 305-1217

CERTIFICATE UNDER 37 CFR §1.8:

The undersigned hereby certifies that the Transmittal Letter and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this __777- day of December,

2005, at (Central Time).